BRAF V600E mutation in metastatic colorectal cancer: Methods of detection and correlation with clinical and pathologic features
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
BRAF V600E mutation in metastatic colorectal cancer: Methods of detection and correlation with clinical and pathologic features
Authors
Keywords
-
Journal
CANCER BIOLOGY & THERAPY
Volume 17, Issue 8, Pages 840-848
Publisher
Informa UK Limited
Online
2016-06-04
DOI
10.1080/15384047.2016.1195048
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial
- (2015) N. Normanno et al. ANNALS OF ONCOLOGY
- Development of a semi-conductor sequencing-based panel for genotyping of colon and lung cancer by the Onconetwork consortium
- (2015) Bastiaan BJ Tops et al. BMC CANCER
- Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer
- (2015) Fotios Loupakis et al. BRITISH JOURNAL OF CANCER
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mismatch Repair Status and BRAF Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS Studies
- (2014) S. Venderbosch et al. CLINICAL CANCER RESEARCH
- BRAFV600E Mutation and Its Association with Clinicopathological Features of Colorectal Cancer: A Systematic Review and Meta-Analysis
- (2014) Dong Chen et al. PLoS One
- Microsatellite instability affecting the T17 repeats in intron 8 of HSP110, as well as five mononucleotide repeats in patients with colorectal carcinoma
- (2013) Srdjan Markovic et al. Biomarkers in Medicine
- PIK3CA, BRAF , and PTEN Status and Benefit from Cetuximab in the Treatment of Advanced Colorectal Cancer—Results from NCIC CTG/AGITG CO.17
- (2013) Christos S. Karapetis et al. CLINICAL CANCER RESEARCH
- BRAFmutation is associated with distinct clinicopathological characteristics in colorectal cancer: a systematic review and meta-analysis
- (2013) C. Clancy et al. Colorectal Disease
- Patients With Colorectal Tumors With Microsatellite Instability and Large Deletions in HSP110 T17 Have Improved Response to 5-Fluorouracil–Based Chemotherapy
- (2013) Ada Collura et al. GASTROENTEROLOGY
- Microsatellite Instability and BRAF Mutation Testing in Colorectal Cancer Prognostication
- (2013) Paul Lochhead et al. JNCI-Journal of the National Cancer Institute
- The Prognostic Role of BRAF Mutation in Metastatic Colorectal Cancer Receiving Anti-EGFR Monoclonal Antibodies: A Meta-Analysis
- (2013) Zi-Xu Yuan et al. PLoS One
- Rare Though Not Mutually Exclusive: A Report of Three Cases of Concomitant KRAS and BRAF Mutation and a Review of the Literature
- (2013) Ibrahim Halil Sahin et al. Journal of Cancer
- Epigenetic and genetic features of 24 colon cancer cell lines
- (2013) D Ahmed et al. Oncogenesis
- A triplet combination with irinotecan (CPT-11), oxaliplatin (LOHP), continuous infusion 5-fluorouracil and leucovorin (FOLFOXIRI) plus cetuximab as first-line treatment in KRAS wt, metastatic colorectal cancer: a pilot phase II trial
- (2012) Z Saridaki et al. BRITISH JOURNAL OF CANCER
- BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer
- (2011) T Yokota et al. BRITISH JOURNAL OF CANCER
- Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer
- (2011) Ben Tran et al. CANCER
- Predictive and Prognostic Roles of BRAF Mutation in Stage III Colon Cancer: Results from Intergroup Trial CALGB 89803
- (2011) S. Ogino et al. CLINICAL CANCER RESEARCH
- Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status
- (2011) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Expression of a mutant HSP110 sensitizes colorectal cancer cells to chemotherapy and improves disease prognosis
- (2011) Coralie Dorard et al. NATURE MEDICINE
- KRAS Mutations Testing in Colorectal Carcinoma Patients in Italy: From Guidelines to External Quality Assessment
- (2011) Nicola Normanno et al. PLoS One
- Combined analysis of specific KRAS mutation, BRAF and microsatellite instability identifies prognostic subgroups of sporadic and hereditary colorectal cancer
- (2010) Inti Zlobec et al. INTERNATIONAL JOURNAL OF CANCER
- Optimizing targeted therapeutic development: Analysis of a colorectal cancer patient population with the BRAFV600E mutation
- (2010) Jeanne Tie et al. INTERNATIONAL JOURNAL OF CANCER
- Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study
- (2010) Jean-Yves Douillard et al. JOURNAL OF CLINICAL ONCOLOGY
- Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
- (2010) Wendy De Roock et al. LANCET ONCOLOGY
- Prognostic and Predictive Biomarkers in Resected Colon Cancer: Current Status and Future Perspectives for Integrating Genomics into Biomarker Discovery
- (2010) S. Tejpar et al. ONCOLOGIST
- Detection ofKRASmutations in colorectal carcinoma patients with an integrated PCR/sequencing and real-time PCR approach
- (2010) Pietro Carotenuto et al. PHARMACOGENOMICS
- Analysis of PTEN, BRAF, and EGFR Status in Determining Benefit From Cetuximab Therapy in Wild-Type KRAS Metastatic Colon Cancer
- (2009) Pierre Laurent-Puig et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic Role of KRAS and BRAF in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial
- (2009) Arnaud D. Roth et al. JOURNAL OF CLINICAL ONCOLOGY
- Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
- (2009) Eric Van Cutsem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Predictive and prognostic value of microsatellite instability in patients with advanced colorectal cancer treated with a fluoropyrimidine and oxaliplatin containing first-line chemotherapy. A report of the AIO Colorectal Study Group
- (2008) C. I. Müller et al. INTERNATIONAL JOURNAL OF COLORECTAL DISEASE
- Wild-TypeBRAFIs Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
- (2008) Federica Di Nicolantonio et al. JOURNAL OF CLINICAL ONCOLOGY
- KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program
- (2008) J. H. J. M. van Krieken et al. VIRCHOWS ARCHIV
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started